Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies

News
Video

Insights into diagnosing EGFR-mutant lung cancer and explores evolving first-line treatment strategies, incorporating recent developments, combinations, and clinical trial data, while addressing challenges in testing and patient management.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Looking Ahead in HER2+ mBC: Unmet Needs, Future Perspectives and Highlights From ASCO 2025
      Looking Ahead in HER2+ mBC: Unmet Needs, Future Perspectives and Highlights From ASCO 2025
      Expert Insights: Later-Line Treatment Strategies for HER2+ Metastatic Breast Cancer
      Expert Insights: Later-Line Treatment Strategies for HER2+ Metastatic Breast Cancer
      Tucatinib Triplet Therapy: Efficacy, Safety and Clinical Decision-Making
      Tucatinib Triplet Therapy: Efficacy, Safety and Clinical Decision-Making
      Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
      Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
      Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
      Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
      Strategic Sequencing in HER2+ Breast Cancer: Optimizing Treatment in the Third Line and Beyond
      Strategic Sequencing in HER2+ Breast Cancer: Optimizing Treatment in the Third Line and Beyond
      Patient Case Presentation: A 47-Year-Old Woman With HER2+ mBC and CNS Progression
      Patient Case Presentation: A 47-Year-Old Woman With HER2+ mBC and CNS Progression
      Outcomes and Factors for Consideration When Choosing Between CAR T Therapies
      Outcomes and Factors for Consideration When Choosing Between CAR T Therapies
      Late-Line R/R: Treatment Landscape
      Late-Line R/R: Treatment Landscape
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      Related Content
      “Exciting Year” for Targeted Therapy Options for Mutated NSCLC, Experts Say

      “Exciting Year” for Targeted Therapy Options for Mutated NSCLC, Experts Say

      Rina Lokaj
      December 24th 2023
      Article

      During the 2023 European Society of Medical Oncology, experts in the field of lung cancer convened to discuss the use of biomarker testing and updated trial results that were presented.

      Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

      Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

      ONCOLOGY Staff
      November 5th 2022
      Article

      A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.

      Recap: Recent Research in Multiple Myeloma

      Recap: Recent Research in Multiple Myeloma

      ONCOLOGY Staff
      November 4th 2022
      Article

      At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.

      Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

      Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

      ONCOLOGY Staff
      September 18th 2022
      Article

      Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.

      Recap: Mayo Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma

      Recap: Mayo Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma

      ONCOLOGY Staff
      July 17th 2022
      Article

      Expert panelists review key data from recent meetings on the management of multiple myeloma and consider how these can be applied to clinical practice.

      Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

      Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

      ONCOLOGY Staff
      July 16th 2022
      Article

      Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.